Vipul Yadav

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from thelaboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system. Complementary to these, Intract has developed unique gastrointestinal (GI) models, which closely reflect the physiological environment of the human GI tract, enabling accurate and predictable in vitro-in vivo correlation.